Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Vyndaqel

- PMLiVE

Bluebird bio leans on pipeline and Zynteglo launch as revenues fall

Revenues down from last year but beat analyst expectations

- PMLiVE

Pfizer’s Vyndaqel is first EU therapy for ATTR cardiomyopathy

EU approval will help drug achieve blockbuster status

AstraZeneca AZ

AZ revenues rise, but it says coronavirus could hit 2020

Product sales up 12% to $23.57bn for the full-year

- PMLiVE

Revenue growth at Ipsen numbs pain of palovarotene calamity

French speciality drugmaker posted €2.58bn sales for the full-year

- PMLiVE

NICE turns down Keytruda/Inlyta combo for kidney cancer

Cost-effectiveness agency says the long-term benefit is uncertain

- PMLiVE

Botox strength bolsters Allergan ahead of AbbVie takeover

Speciality drugmaker posted a 6.6% sales increase in the last quarter

- PMLiVE

Skyrizi, Rinvoq help AbbVie weather Humira slowdown

The company expects overall earnings growth to be around 8% this year

- PMLiVE

Celgene drugs drive BMS to a buoyant Q4, but Opdivo stalls

BMS share price up by 3% on the back of results

- PMLiVE

GSK considers more divestments to help R&D push

Turns priority to future growth drivers and R&D investment

- PMLiVE

Sanofi highlights MS drug data as it swings to a loss in Q4

Reported a €10m net loss in the quarter

- PMLiVE

Lilly posts higher-than-expected profit as new drugs lift outlook

Sales boosted by growth of Trulicity and Taltz

- PMLiVE

Roche posts minor sales miss in Q4 as biosimilar pressure grows

Swiss pharma still managed an 8% increase in pharma sales

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links